Literature DB >> 7235274

Pharmacokinetics and plasma binding of thiopental. I: Studies in surgical patients.

D J Morgan, G L Blackman, J D Paull, L J Wolf.   

Abstract

The pharmacokinetics and plasma protein binding of thiopental were investigated in 5 female patients who received a bolus intravenous dose of the drug for induction of anesthesia for gynecologic surgery. Blood samples were collected for 3 to 4 days after the dose. Plasma protein binding determinations were also carried out by ultrafiltration and equilibrium dialysis on samples from a panel of healthy volunteers. Plasma concentrations of thiopental were determined by reverse-phase, high-performance liquid chromatography. The coefficient of variation of the method was 2.8 per cent (n equals 10). In healthy volunteers, the plasma protein binding of thiopental was concentration dependent. Percentage bound ranged from 96.7 (n equals 4, SD equals 0.8) at 150 micrograms/ml. Therefore, saturation of binding sites on rapid administration of the drug may occur, exposing vital organs to unexpectedly high concentrations of free drug. Values of the fraction of thiopental bound in plasma obtained from the surgical patients during the hour following drug administration were similar to values obtained in healthy volunteers at comparable concentrations. Mean pharmacokinetic parameters obtained for thiopental in the surgical patients were as follows: initial distribution volume 13.81 (SD equals 9.4), apparent volume of distribution 233 1 (SD equals 98), volume of distribution at steady state 97.51 (SD equals 40), elimination half-life 11.5 h (SD equals 1.0) and systemic plasma clearance 0.150 l/min (SD equals 0.063). None of these parameters correlated with body weight. Values reported by other workers vary from ours and this variation may be explained by the much shorter duration of blood collection used in those studies.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7235274     DOI: 10.1097/00000542-198106000-00005

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  13 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Treatment of local anesthetic toxicity.

Authors:  R F Gerlach; J E Tanus-Santos
Journal:  Anesth Prog       Date:  1999

Review 3.  Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.

Authors:  B N Swerdlow; F O Holley
Journal:  Clin Pharmacokinet       Date:  1987-02       Impact factor: 6.447

4.  A survey of pharmacokinetic data from pregnant women.

Authors:  A J Cummings
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

5.  Elimination kinetics of thiopentone in mothers and their newborn infants.

Authors:  F Gaspari; G Marraro; G F Penna; R Valsecchi; M Bonati
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Plasma binding of thiopentone in late pregnancy.

Authors:  D J Morgan; C T Toh; G L Blackman; J D Paull
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

7.  Stereoselective interaction of thiopentone enantiomers with the GABA(A) receptor.

Authors:  D J Cordato; M Chebib; L E Mather; G K Herkes; G A Johnston
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

8.  Evaluation of infusion regimens for thiopentone as a primary anaesthetic agent.

Authors:  D P Crankshaw; N E Edwards; G L Blackman; M D Boyd; H N Chan; D J Morgan
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  [Hemodynamic interferences between diltiazem and thiopental--experimental study in the pig].

Authors:  M Pierrot; M Blaise; S Hugon; F Bonnel; M Cupa
Journal:  Can Anaesth Soc J       Date:  1984-03

Review 10.  Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure.

Authors:  G Heinemeyer
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.